论文部分内容阅读
卵巢癌占女性生殖系统肿瘤的25%,是致死性最强的妇科恶性肿瘤[1]。近年来,人们开始探索分子靶向治疗在卵巢癌中的应用,特别是对抗血管生成药物治疗卵巢癌的研究[2-3]。贝伐单抗是目前临床应用最多的人源化的抗血管内皮生长因子(VEGF)单克隆抗体,其基本作用机制是与VEGF结合后使其失去活性从而抑制肿瘤血管的
Ovarian cancer accounts for 25% of female reproductive system tumors, is the most lethal gynecological malignancy [1]. In recent years, people began to explore the use of molecular targeted therapy in ovarian cancer, especially for antiangiogenic drugs in the treatment of ovarian cancer [2-3]. Bevacizumab is the most clinically applied humanized monoclonal antibody against vascular endothelial growth factor (VEGF) at present. The basic mechanism of action is that it binds to VEGF, inactivates it and thus inhibits tumor blood vessels